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Men with metastatic castration-resistant prostate cancer (mCRPC) carry poor prognosis despite the use of
docetaxel-based regimens which has modest survival benefit shown by randomized clinical trials. Significant
progress in the discovery of novel therapeutic agents has been made in the past few years. While sipuleucel-T,
cabazitaxel, and abiraterone gained regulatory approval in 2010 and 2011, several highly promising candidates/
regimens have failed in large scale clinical trials. Challenges remain to optimize the design and interpretation of
clinical trial results and develop more effective strategies for mCRPC. In this review, we examined the positive and
negative clinical trials in mCRPC in the past and discussed the various aspects of clinical trial design including
selection of targets and appropriate outcome measures, biomarker development and implementation, and
strategies for combination therapy.Introduction
Prostate cancer is the most common non-cutaneous malig-
nancy and the second leading cause of cancer deaths among
men in the United States, with an estimated incidence of
241,740 new cases diagnosed and approximately 28,170 men
expected to die of the disease in 2012 [1]. Men with meta-
static castration-resistant prostate cancer (mCRPC) have a
poor prognosis with a median survival of 1–2 years, and until
recently, treatment options that improved survival in this set-
ting were limited to docetaxel-based regimens [2,3]. The
responses to docetaxel and prednisone are generally short-
lived with a modest survival benefit. Recent major advances
have resulted in the regulatory approval of sipuleucel-T [4]
and cabazitaxel [5] in 2010 and abiraterone acetate (AA) [6]
in 2011 for mCRPC patients. Despite these additions to the
therapeutic arsenal for this patient population, mCRPC
remains incurable and the demand for novel therapies will
continue with the pursuit of new druggable targets. In the
meantime, we have also witnessed the failure of several
highly promising candidates/regimens in late stage of devel-
opment, reminding us that the road to fighting against* Correspondence: wdfigg@helix.nih.gov
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reproduction in any medium, provided the orprostate cancer is still paved with immense difficulties. Chal-
lenges remain for clinical scientists to improve upon existing
treatment paradigms and develop more effective strategies
for mCRPC. Careful scrutiny of past positive and negative
clinical trials will allow us to better optimize target selection,
design meaningful outcome measures, and advance bio-
marker development with implementation in future clinical
trials.Target selection
Unraveling the molecular make up of cancer cells has
resulted in the successful development of specific targeted
therapies directed at particular molecular pathways. Studies
involving imatinib for CML and GIST, trastuzumab for
HER-2 positive breast cancer, crizotinib for ALK-mutated
lung cancer, and vemurafenib for BRAF-mutated advanced
melanoma have all confirmed the significance and feasibil-
ity of targeted therapy [7]. Considerable efforts have been
made in searching for such targets for prostate cancer
patients. Our understanding of the biologic and molecular
driving force of prostate cancer growth and progression in
the past few years have resulted in investigations of numer-
ous novel targeted therapies, including androgen receptor
(AR) targeting agents, tyrosine kinase inhibitors (TKIs),
antiangiogenic agents, endothelin receptor antagonists,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[8-10]. Many of them have either received FDA approval or
moved to the frontline of late stage development based on
improvement of soft intermediate surrogate markers in small
phase I/II trials. As bone metastasis is common in patients
with mCRPC, agents targeting the bone microenvironment
have been successful not only in the prevention of skeletal-
related events in men with bone metastases from mCRPC,
such as with denosumab and radium-223, but also in im-
proving survival, such as with radium-223 [11,12].
The progression of mCRPC can occur as a result of AR
activation despite low levels of androgens. Numerous mo-
lecular and genetic aberrations have been postulated to be
responsible for gain-of-function changes in the AR signaling
pathway under androgen deprivation. This includes intratu-
moral androgen synthesis, AR protein overexpression, AR
gene amplification or point mutations, constitutively active
truncated AR splice variants, disturbance of AR-coactivator-
corepressor complex, and ligand-independent AR activation
by kinase cross-talk [8,13]. Patients who failed primary and/
or secondary hormonal therapies are still candidates for
more potent novel hormonal agents. AA, a specific inhibitor
of the key androgen synthesis enzyme CYP17, and
MDV3100, a second generation antiandrogen, represent two
such novel therapies targeting the androgen signaling axis in
mCRPC. In the recent phase III trial of AA (COU-AA-301)
[6], a 35% reduction in the risk of death (HR=0.65;
p<0.0001) and a 36% increase in median survival (14.8 vs.
10.9 months) were observed in patients treated with AA plus
prednisone, compared with patients who received placebo
plus prednisone. Encouraging antitumor activity was also
recorded in a multicenter phase I/II study of MDV3100 with
56% PSA response and 22% response in soft tissue diseases
[14], A randomized, double-blind, multinational phase III
trial (AFFIRM), comparing MDV3100 with placebo in
mCRPC patients previously treated with docetaxel, was ter-
minated early due to a 4.8 months absolute survival advan-
tage (18.4 vs. 13.6 months) per interim analysis [15].
On the other hand, zibotentan, an endothelin A receptor
antagonist blocking endothelin-mediated activation of mul-
tiple signaling transduction pathways [16], showed strong
inhibition of prostate cancer cell proliferation and delayed
progression of bone metastases in preclinical studies [17].
Phase II data demonstrated a statistically significant im-
provement in overall survival (OS) for patients treated with
zibotentan [18]. Interestingly, the study did not meet its pri-
mary endpoint of time to progression. Moreover, at the final
analysis (median follow-up of 22 months), the absolute OS
benefit diminished down to 3.6 months from 7.2 months.
[19] Based on the initial OS benefit, an expanded phase III
program was launched and included three trials (ENTHUSE
M0, ENTHUSE M1, and ENTHUSE M1c) in disease ran-
ging from non-metastatic CRPC (M0) to mCRPC (M1 and
M1c), evaluating either single-agent zibotentan (M0 andM1) or in combination with docetaxel (M1c) [20]. However,
recent analysis of M1 showed that the study failed to meet
its primary endpoint of OS [21]. M0 was also terminated
following an early efficacy review indicating that zibotentan
monotherapy was unlikely to meet its primary efficacy end-
points. Whether targeting the endothelin axis in prostate
cancer is a valid approach remains an open question and
results from M1c are eagerly awaited.
Similar disappointing results were reported that led to
the termination of the late-stage trial of sunitinib, an anti-
angiogenic TKI, in combination with prednisone as
second-line therapy for mCRPC patients due to the lack of
OS prolongation, despite an improvement in progression-
free survival (PFS) (5.6 vs. 3.7 months; HR=0.74; P= .0077)
[22]. The initiation of this phase III trial was based on the
modest anti-tumor activity of sunitinib in two phase II trials
[23,24]. One trial showed 6% prostate-specific antigen
(PSA) response rate and only one out of 29 evaluable
patients manifested as partial response radiographically at
week 12 [23]. Some discordance of PSA elevation with
radiographic response was observed and considered con-
sistent with PSA dynamics under the unique influence of
TKIs, as previously established in a phase II trial of sorafe-
nib in mCRPC [25]. Another phase II trial reported weak
antitumor activity with 12.1% PSA response rate and 11.1%
radiographic response with single-agent sunitinib [24]. Yet
a large phase III trial was implemented since 2008 and has
proved to be fruitless. Both examples demonstrate the need
to be more selective of agents to bring forward to be tested
in the phase III setting.
While recognizing the essential role of early clinical trials
in enhancing our understanding of disease biology, we
must be conscious about the limitations in interpreting
results owing to insufficient sample size, unreliable surro-
gate markers, or suboptimal outcome measures. Undoubt-
edly, such trials are required to facilitate efficient screening
for active compounds for further clinical development.
Selecting appropriate targets for development in phase III
trials and the decision to move the drug forward can be
difficult at times when early trials reveal only mild clinical
activity based on current, suboptimal trial designs. A more
stringent and validated benchmark in assessing a meaning-
ful clinical benefit is in enormous demand.
Appropriate outcome measures
The efficient design of phase II trials to identify active com-
pounds for phase III testing remains a challenge. Alternate
end points for screening phase II studies are urgently needed
to limit the high incidence of negative phase III trials.
Choosing the most suitable primary endpoints for prostate
cancer trials has been challenging historically. Although OS
is the gold standard for demonstrating clinical benefit due to
its objectivity, it requires larger patient numbers and longer
follow-up. Survival analysis may also be confounded by
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drug is discontinued. Valid intermediate surrogate endpoints
have been the center of debate for the past few years. Ana-
lyses of PSA response rates, objective response rates and
PFS have all been proposed as means to accelerate the drug
development process.
Most phase II trials have used PSA decline of more than
50 percent as the primary endpoint, based on its high pre-
dictive value of survival from a multivariate analysis [26]
and the prostate cancer clinical trials working group’s
(PCWG1) recommendation [27]. Some trials also incorp-
orate 3-month 30% PSA decline since it was found to be
the optimal biochemical surrogate from a retrospective
analysis of the phase III SWOG 9916 trial [28]. However,
the limitations of PSA and PSA-based surrogates in pre-
dicting survival have been increasingly recognized. In TAX
327, despite a statistical significant improvement in the
rates of PSA response in patients taking docetaxel weekly
compared to mitoxantrone (48% vs. 32%, p < 0.001, re-
spectively), there was no difference in OS between the two
groups [3]. Prospective trials are required to validate PSA-
based markers in selected patient populations before they
can be confidently used as predictors of survival and as
screening tools in early phase trials. Most phase II trials de-
fine disease progression by either radiographic or PSA pro-
gression as defined by PCWG1 and PCWG2 [27,29]. For
consistency of reporting clinical trials, the PCWG2 defined
PSA progression as the date that an increase of 25% or
more and absolute increase of 2 ng/mL or more from the
nadir are documented. For patients who have an initial
PSA decline during treatment, this must be confirmed by a
second value 3 or more weeks later. The significance of
solely using PSA progression without evidence of radio-
graphic or symptomatic progression became questionable
as we gained more insight into the mechanisms of action
of phase II agents and the natural history of this disease.
Several trials involving TKIs have observed rising PSAs
after treatment [23,25]. The discordance between the PSA
increase and radiographic improvement may be due to the
effect of noncytotoxic agents modulating PSA secretion in-
dependent of its activity on tumor suppression [30]. With-
out other well-defined indicators for disease progression,
PSA progression is no longer considered representative of
treatment failure [29], thus, allowing these agents to be
fully evaluated in patients to achieve the maximum pos-
sible benefit. As such, the interpretation of post-therapy
PSA changes as an outcome measure in the era of targeted
agents is of unclear significance [31].
Response rates have also been assessed in patients with
measureable diseases on CT scans. However, the clinical pic-
ture of mCRPC is dominated by bone metastases in 90-95%
of the patients. Radionuclide bone scan is routinely used to
assess these bony lesions but the criteria for response
categorization are not well-defined and reported in clinicaltrials. Other imaging modalities (MRI and PET) to assess
bone metastasis are still under investigation [32]. Moreover,
as cytostatic biologic agents are increasingly being evaluated
in clinical trials, the expectation of tumor shrinkage by these
agents seems unrealistic. In a small number of patients, usu-
ally less than half of the study accrual [33], with soft tissue
or visceral metastases that are evaluable, the response rate
defined by RECIST criteria is far from being acceptable for
cytostatic agents. In the phase II sunitinib and sorafenib
trials, the response rates were in 2/18 and 1/23 (combined
stage I and II) patients, respectively [24,25,34]. Continuous
application of this intermediate surrogate marker in our trial
design will likely neglect the potential benefit of these agents
in delaying tumor progression. In this regard, the PCWG2
recommended the utilization of prevent/delay endpoints in
these trials rather than control/relieve/eliminate endpoints
commonly used for cytotoxic agents [29]. Thus, an alterna-
tive endpoint may be needed for this group of targeted
agents.
Whether PFS is a justifiable intermediate surrogate end-
point in prostate cancer is still an open question. PFS is
defined as the time from study entry or randomization of a
patient until objective tumor progression or death. The use
of PFS in trials has several advantages that include a smaller
sample size and shorter duration of follow-up. PFS is also
not affected by crossover or subsequent treatments. Various
definitions for PFS, including PSA, radiographic changes,
new metastatic lesions, and disease-related symptoms, have
been used in clinical practice. However, data has shown that
current measures of PFS for men with CRPC are not strong
surrogates for OS [35,36]. It again was demonstrated by the
failed phase III CALGB 90401 trial comparing docetaxel
with or without bevacizumab in mCRPC with OS as the
primary endpoint [37]. The development of this trial is
based on favorable PFS of 8 months in bevacizumab arm in
phase II CALGB 90006 trial [38]. Although improvements
were seen again in PFS, the bevacizumab arm did not im-
prove OS and was associated with greater morbidity and
mortality in this large scale trial. In the phase III SPARC
(Satraplatin and Prednisone Against Refractory Cancer)
trial evaluating the use of satraplatin as second-line therapy
in mCRPC, a composite PFS end point was utilized. It con-
sisted of radiographic progression, symptomatic progres-
sion (pain, analgesics, ECOG performance status, weight
loss, etc.), and occurrences of skeletal-related events [39].
Although the treatment of satraplatin plus prednisone was
associated with a statistically significant improvement
in the composite PFS endpoint (11.1 vs. 9.7 weeks;
P <0.0001), it did not translate into a meaningful clinical
benefit such as a prolonged survival [39]. A meta-analysis
of multiple trials, to verify potential intermediate surro-
gates, detected that PFS is an acceptable surrogate in
advanced colorectal and ovarian cancer, but not in breast
and prostate cancer [40]. It is unclear whether the
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inance of bone metastasis not assessable by RECIST in the
majority of breast or prostate cancer cases. PFS appears to
not be an optimal surrogate for OS in circumstances where
disease is confined to bone. The current guideline only
requires either “no new lesions” or “new lesions” being
documented [29] for bone disease assessment and may
have overlooked subtle changes in bone which carries
meaningful survival value. The ability to accurately deter-
mine disease status in prostate cancer, i.e. PFS, is likely
compromised given the lack of reproducible and effective
modalities to delineate changes of bone metastases.
Molecular phenotypes and biomarker
development
Given that there are no validated surrogates of OS to as-
sess early clinical benefit in CRPC trials, incorporation of
relevant biomarkers in early phases of clinical develop-
ment is essential to improve the success of late phase III
testing. Clinical trial design is challenged by the ability to
correlate clinical outcome with specific biomarkers reflect-
ive of the tumor phenotype with predictive or prognostic
value. PSA has long been used as prognostic marker but
due to its limitations, various PSA-based biomarkers were
explored such as PSA velocity, PSA doubling time, etc. A
systematic review of the literature highlighted conflicting
data from heterogeneous studies on the use of such bio-
markers as prognostic risk factors; [41] thus, the PCWG2
has discouraged the use of post-therapy changes of PSA
doubling time as a primary endpoint [29].
However, resistance is bound to occur as the median dur-
ation of radiographic response is 5.6 months and 47 weeks,
in patients treated with AA and MDV3100, respectively
[14]. Acquired drug resistance has been a problem with
many other targeted cancer agents. Finding strategies to
overcome resistance is of paramount importance. If predict-
ive marker(s) for androgen deprivation therapy (ADT)
could be pinpointed to patients who are more likely to
benefit, then unnecessary exposure of toxicity to non-
responders would be avoided and the efficacy of these novel
agents would be enhanced. Genetic biomarkers or finger-
prints of mCRPC will yield specific information about the
tumor and lead to a better understanding of the disease
and the development of more effective treatment options.
In addition, depending on the prior therapy received, meta-
static tumors might acquire mutations or genetic changes
that were clonally selected to confer a survival advantage.
Obtaining tissue samples at various stages of the disease for
verification of the evolving biology of prostate cancer pro-
gression may be particularly difficult owing to the heteroge-
neous and multifocal nature of the disease. Many studies
have attempted to identify prostate cancer signature gene(s)
and other genetic alterations, and new findings are emer-
ging. A population-based study proved the prevalence ofETS fusions with TMPRSS2 as the first recurrent genomic
alteration in prostate cancer. The ETS-related gene (ERG)
is the most common fusion partner for the androgen-
regulated gene TMPRSS2 [42]. The fact that ETS fusion-
positive prostate cancer usually carries a more aggressive
phenotype but still respond to ADT owing to its 5’
androgen-regulated partner, makes it an ideal potential pre-
dictive biomarker for ADT. In fact, increased prevalence of
patients with hormone-regulated ERG gene rearrangement
was identified in a group of mCRPC patients treated with
AA who had more than 90% PSA declines [43]. However,
in an analysis of TMPRSS2-ERG fusion status in patients
enrolled in sequential phase II AA trials, similar rate of
PSA response were indentified in both groups regardless of
the presence of TMPRSS2-ERG fusion. Thus, the predictive
value of TMPRSS2-ERG for the response to hormonal
treatment is still uncertain at this time. Moreover, it has
been technically challenging in developing inhibitors of
ETS fusions targeting the 3’ ETS due to its poor accessibility
[44]. Newer technology such as RNA interference might
hold therapeutic promise and needs to be further explored
[45]. Other than gene fusions, germline DNA polymorph-
isms may be associated with the response or resistance to
ADT and increased uptake of testosterone in advanced
prostate cancer [46]. If these genetic biomarkers can be
validated in a large cohort of patients, they may be incorpo-
rated into future prospective clinical trials as both prognos-
tic biomarkers to identify high-risk patients and predictive
markers for patient stratification before initiating therapy.
Investigations are ongoing to develop more specific and
sensitive tools to detect bone changes in prostate cancer.
PET scans with different tracers have been studied with
various success for its ability to detect metastatic diseases,
monitor response to therapies and prognosticate OS [47].
Digital-contrast enhanced-magnetic resonance imaging
was also employed. In a phase II trial using AZD2171, it
exhibited correlation between targeted activity and tumor
response [48]. Results from all these efforts will likely con-
tribute to guideline updates of the criteria for evaluation
of bone diseases in the near future.
Circulating tumor cell (CTC) count has also been widely
implemented in various clinical trials and can be used for
risk-stratification, molecular subclassification, or as a sur-
rogate endpoint in treatment efficacy studies. The decline
of CTC count after various treatments has been associated
with improved OS [49,50]. The clinical utility of monitor-
ing CTC changes with treatment is currently undergoing
the efficacy-response biomarker qualification process, spe-
cifically as an intermediate endpoint for detecting survival
benefit from AR-targeted therapies. The enumeration of
CTC has been incorporated into several phase II studies
including trials of AA [51-53] with additional surrogacy
analyses embedded in phase III survival-based trials. While
changes in CTCs have also been proposed as possible
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such as sipuleucel-T or ipilimumab, their role remains to
be determined. Molecular determinants can be identified
and characterized in CTCs as potential predictive markers
of drug sensitivity or resistance to treatment. There are a
range of assessment methods that are in various stages of
development, validation, and clinical testing. Presently,
CellSearch (Veridex) is the only CTC assay that is FDA-
cleared for use in the clinic. Further development of CTC
evaluation technologies could facilitate the subclassification
of patients based on molecular profiles or a CTC-derived
molecular signature to allow for patient selection for tar-
geted therapies or to guide treatment selection. Prospect-
ively designed studies should further assess the role of
CTC biomarkers as strong intermediate endpoints for clin-
ical benefit, in determining prognosis and monitoring
treatment effects to incorporate into clinical practice, and
for accelerating drug development.Strategies for combination therapies
Several new treatment options have recently become avail-
able for patients with mCRPC. Clinicians are now faced
with the challenge of understanding how to best utilize
these newer therapies. The post-docetaxel era has seen nu-
merous trials combining docetaxel with multiple agents
with distinct mechanisms of action including TKIs, angio-
genic inhibitors, bone-targeted agents, BCL-2 inhibitors,
chemotherapies, immunologic agents, and vitamin D ana-
logs [10]. Analysis on a phase II combination trial of suniti-
nib and docetaxel showed a 56% PSA response rate and
42% RECIST-defined response rate [54]. A phase III rando-
mized trial with this combination is currently underway.
However, two recent phase III trials combining docetaxel
with an antiangiogenic agent, either bevacizumab (CALGB
90401) or lenalidomide (MAINSAIL), failed to improve OS
in mCRPC patients [55,56]. Indeed, blocking neovasculari-
zation by VEGF antibody was found to induce hypoxia
which in turn up-regulate angiogenic factors such as bFGF,
chemokines and ephrin, and angiopoietin families, leading
to anti-angiogenesis rescue [57]. To overcome the hurdle
of multiple pre-existing or induced pro-angiogenic factors,
a strategy combining docetaxel with dual antiangiogenic
agents with distinct anti-angiogenic properties, bevacizu-
mab and thalidomide, represented a new approach, and
was demonstrated in a phase II trial. It resulted in high re-
sponse rates in PSA changes and measurable diseases, and
an encouraging estimated median survival rate in this pa-
tient population [58]. This demonstrated the feasibility
and potential activity of combining antiangiogenic agents
of different mechanisms of action with docetaxel.
Currently, an ongoing Phase II trial is investigating the
four-drug treatment regimen with thalidomide being
replaced by lenalidomide, a derivative of thalidomide withmore potent immunostimulatory and antiangiogenic activ-
ity but less toxicity (ClinicalTrials.gov NCT00942578).
Hormonal therapy combined with docetaxel was also
tested in a phase I trial using ketoconazole and docetaxel.
Although docetaxel was given weekly (since the trial was
designed and implemented before the availability of the
TAX 327 data), active tumor response was observed in 62%
of patients with PSA response, and 28% with partial re-
sponse in measurable disease [59]. This trial has suggested
the combination of cytotoxic and hormonal agents might
render an additive and possible synergistic antitumor activ-
ity. Several multicenter phase III trials combining first-line
conventional hormonal agents with docetaxel are currently
ongoing to address the question regarding early versus late
initiation of chemotherapy in metastatic, hormonal-sensitive
patients (ClinicalTrials.gov NCT00268476, NCT00104715).
The potency of ketoconazole in controlling disease/PSA
progression is usually not durable as adrenal androgen
levels were increased relative to their nadir at the time of
disease progression [60]. AA, on the other hand, has been
shown to be able to continuously inhibit adrenal androgen
synthesis even at the time of disease progression, as evi-
dent by continued suppressed level of serum androgen in
several phase I/II studies of AA [51,61]. This observation
excluded the possibility of resistance to AA due to
mutated CYP17 and inefficient androgen blockade. It
affirmed that the enzyme remained a valid target and still
required sustained application even at the time of progres-
sion and initiation of subsequent therapies. Perhaps a
combination therapy that integrates uninterrupted andro-
gen deprivation by a novel, potent agent like AA and
cytotoxic agents with a proven survival benefit such as
docetaxel or cabazitaxel, will likely provide synergistic
clinical benefit and overcome resistance in mCRPC
patients. Such trials are currently underway in phase I
testing (ClinicalTrials.gov NCT01400555, NCT01511536).
Conclusions
In order to achieve sustained success in drug development,
researchers must remain conscious of the challenges and
limitations in conducting clinical trials in prostate cancer.
Given the heterogeneity of the disease at the molecular
level, it remains a challenge to identify suitable druggable
target(s). Subsequent molecular studies are warranted to
justify and/or validate the targeted therapy under investiga-
tion. Failures from several recent phase III trials based on
expedited approaches in advancing a drug from phase I/II
to III despite weak early phase trial data have taught us to
be more selective about what agents to bring forward to be
tested in the phase III setting. Reducing drug failures early
in development is far more important than filling a pipeline
with poorly chosen late-stage drugs.
Biomarkers can revolutionize both the development and
use of targeted therapeutics, but is contingent upon the
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qualification process, a biomarker should be tested in
phase I and II efficacy trials to measure its robustness and
validate its association with predicted clinical outcome.
The incorporation of mechanism-based biomarker end-
points into early clinical trials has facilitated in making
early “go-no go” decisions in drug development [62,63]
and reduces the risk of drug failures in large-scale, costly
phase III trials. Finding reliable indicators of clinical effi-
cacy of noncytotoxics or targeted agents is an area in need
of further development. Existing intermediate surrogate
biomarkers and easily accessible surrogates, such as CTC,
can be analyzed and validated prospectively in large phase
III trials and can be vital to the understanding of the bene-
fits of particular agents and treatment combinations.
Whether OS remains the gold standard or the reliability of
PFS as a surrogate marker for emerging therapeutics will
need to be further clarified in future studies.Appendix
Metastatic castration resistant prostate cancer: Pro-
gressive metastatic prostate cancer despite castrate level
of testosterone.
Surrogate endpoints: Outcome measures that are
intended to substitute for a clinical endpoint and are
expected to predict clinical benefit based on scientific
evidence.
Promiscuous androgen receptor: Androgen receptor
protein that acquired mutations leading to the activation
of the androgen-signaling axis with ligands other than
testosterone and dihydrotestosterone.
Circulating tumor cell count: Enumeration of subpo-
pulation of tumor cells derived from the primary cancer
site which has been shown to correlate with survival in
metastatic prostate cancer.
Prostate cancer clinical trials working group: A group
of expert clinical investigators who meet periodically in an
effort to standardize the eligibility and outcome measures
in clinical trials in patients with metastatic castration re-
sistant prostate cancer.Abbreviations
mCRPC: metastatic castration-resistant prostate cancer; AA: abiraterone
acetate; AR: androgen receptor; TKI: tyrosine kinase inhibitor; OS: overall
survival; PFS: progression-free survival; PSA: prostate-specific antigen;
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